Proteostasis Therapeutics is developing novel disease-modifying therapeutics that modulate protein chaperone and proteasomal degradation pathways within the cell to enhance the function and capacity of the protein homeostasis network or Proteostasis Network. Our product candidates correct for imbalances in the Proteostasis Network resulting from the cumulative effects of disease, genetic mutations, environmental factors, and aging. Our lead programs are in cystic fibrosis and neurodegenerative diseases.

Key Milestones

  • Transition key programs to development in 2014
  • Announce new partnerships in 2014
  • File an IND for the cystic fibrosis program in 2015
  • Seek in-licensing/acquisition opportunities